JSPRW
MaterialsJasper Therapeutics Inc - Warrants (24/09/2026)
Live · NASDAQ · May 9, Close
What's Moving JSPRW Today?
No stock-specific AI insight has been generated for JSPRW yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.02
Fundamentals
Trading
JSPRW News
16 articles- Evercore ISI Lowers its Price Target on Jasper Therapeutics (JSPR) to $7Yahoo Finance·Apr 7, 2026
- Jasper Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate UpdateYahoo Finance·Mar 30, 2026
- Why UBS Started Jasper Therapeutics (JSPR) at Neutral Despite Progress in BriquilimabYahoo Finance·Mar 29, 2026
- Jasper Therapeutics to Present at 46th Annual TD Cowen Healthcare ConferenceYahoo Finance·Feb 24, 2026
- Jasper Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateYahoo Finance·Nov 10, 2025
- Jasper Therapeutics to Present at Upcoming Investor ConferencesYahoo Finance·Nov 4, 2025
- Positive Signs As Multiple Insiders Buy Jasper Therapeutics StockYahoo Finance·Oct 10, 2025
- Jasper Therapeutics Announces Proposed Public Offering of Common Stock, Pre-Funded Warrants and Common WarrantsYahoo Finance·Sep 18, 2025
- Jasper Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateYahoo Finance·Aug 13, 2025
- Jasper Therapeutics Announces Corporate Reorganization and Other Cost Cutting Measures to Extend Cash RunwayYahoo Finance·Jul 9, 2025
- Jasper Therapeutics to Halt Asthma Study After Drug Batch Issue; Shares Fall Pre-BellYahoo Finance·Jul 7, 2025
- Jasper Therapeutics Reports Clinical Data Update from Briquilimab Studies in Chronic Spontaneous UrticariaYahoo Finance·Jul 7, 2025
- Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible UrticariaYahoo Finance·Jun 14, 2025
- Jasper Therapeutics Announces Briquilimab Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) Annual CongressYahoo Finance·Jun 3, 2025
- Jasper Therapeutics (NASDAQ:JSPR) Will Have To Spend Its Cash WiselyYahoo Finance·May 29, 2025
- Jasper Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate UpdateYahoo Finance·May 12, 2025
All 16 articles loaded
Price Data
52-Week Range
$0.02
Fundamentals
Trading
About Jasper Therapeutics Inc - Warrants (24/09/2026)
Jasper Therapeutics Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for serious diseases, leveraging its proprietary hematopoietic cell transplantation platform. Its lead candidate, JSP191, targets blood disorders and has shown promising results in early clinical trials, suggesting significant potential for improved patient outcomes and safety. With a strong pipeline and a seasoned team of industry professionals, Jasper Therapeutics is positioned to make transformative contributions to the field of cell therapy and regenerative medicine as it advances through clinical development stages.